Literature DB >> 16495261

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Sven Enterlein1, Kelly L Warfield, Dana L Swenson, David A Stein, Jeffery L Smith, C Scott Gamble, Andrew D Kroeker, Patrick L Iversen, Sina Bavari, Elke Mühlberger.   

Abstract

Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495261      PMCID: PMC1426423          DOI: 10.1128/AAC.50.3.984-993.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Evaluation of antisense mechanisms of action.

Authors:  C Ghosh; D Stein; D Weller; P Iversen
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Morpholino oligos: making sense of antisense?

Authors:  Janet Heasman
Journal:  Dev Biol       Date:  2002-03-15       Impact factor: 3.582

3.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.

Authors:  Lisa E Hensley; Howard A Young; Peter B Jahrling; Thomas W Geisbert
Journal:  Immunol Lett       Date:  2002-03-01       Impact factor: 3.685

5.  Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

Authors:  M Gupta; S Mahanty; M Bray; R Ahmed; P E Rollin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.

Authors:  Douglas W Leaman; Frank J Longano; James R Okicki; Kenneth F Soike; Paul F Torrence; Robert H Silverman; Hagen Cramer
Journal:  Virology       Date:  2002-01-05       Impact factor: 3.616

7.  Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers.

Authors:  D A Stein; D E Skilling; P L Iversen; A W Smith
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-10

8.  Infectivity-enhancing antibodies to Ebola virus glycoprotein.

Authors:  A Takada; S Watanabe; K Okazaki; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Donald K Nichols; William D Pratt; Robert Blouch; David A Stein; M Javad Aman; Patrick L Iversen; Sina Bavari
Journal:  PLoS Pathog       Date:  2006-01-13       Impact factor: 6.823

View more
  57 in total

1.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

2.  A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus.

Authors:  Jeffrey K Stone; Rene Rijnbrand; David A Stein; Yinghong Ma; Yan Yang; Patrick L Iversen; Raul Andino
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

3.  Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Rheba S Bonaparte; Deendayal Patel; David A Stein; Patrick L Iversen
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

4.  Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; Jay C Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

5.  Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8.

Authors:  Toru Kubota; Mayumi Matsuoka; Tsung-Hsien Chang; Mike Bray; Steven Jones; Masato Tashiro; Atsushi Kato; Keiko Ozato
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

6.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

7.  Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Deendayal Patel; Yuchen Nan; Sumin Fan
Journal:  Antivir Ther       Date:  2011

8.  An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.

Authors:  Emily V Nelson; Jennifer R Pacheco; Adam J Hume; Tessa N Cressey; Laure R Deflubé; John B Ruedas; John H Connor; Hideki Ebihara; Elke Mühlberger
Journal:  Antiviral Res       Date:  2017-08-12       Impact factor: 5.970

9.  Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Kinola J N Williams; Joan B Geisbert; Anders Leung; Friederike Feldmann; Lisa E Hensley; Heinz Feldmann; Steven M Jones
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.

Authors:  Verena Krähling; Olga Dolnik; Larissa Kolesnikova; Jonas Schmidt-Chanasit; Ingo Jordan; Volker Sandig; Stephan Günther; Stephan Becker
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.